Please login to the form below

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

Post-merger Celgene to lead pharma growth

Celgene also has five potential blockbusters in its late-stage pipeline, including MS treatment ozanimod and myelodysplastic syndromes/beta thalassemia candidate luspatercept, which have both recently been filed.

Latest news

Celgene files luspatercept ahead of key merger vote

The drug is one of five late-stage pipeline drugs from Celgene tipped for blockbuster status (the first being the just-re-filed ozanimod) and the filing comes just days ahead
FDA approves Novartis' next-gen MS drug Mayzent

The approval comes just one day after Celgene its MS treatment, ozanimod, which is likely to be a close rival to Novartis' drug once approved.
Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger. Celgene has re-submitted its multiple sclerosis (MS) drug ozanimod to the FDA, more than a year on since the filing was ... Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, and is also
BMS and Celgene announce $74bn merger

s slip-ups, including the botched filing of MS candidate ozanimod a year ago. ... It also TYK2 and ozanimod in immunology and inflammation, and two more in haematology: luspatercept and fedratinib.
Celgene to launch five new products through to 2020

The five blockbusters-in-waiting are multiple sclerosis therapy ozanimod – which has been delayed by the FDA’s refusal to accept the company’s regulatory filing earlier this year – fedratinib for

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Pharma deals in July 2015

Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Midweight Brand Planner: Up to £50, 000

Head of Partnerships - Competitive - London: Competitive Salary Offered

Senior / Principal Medical Writer / ETL - MedComms - HOME BASED ...: D.O.E

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Playing Mind Games: To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists: P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future: As I sit here at another pharma conference, I start to reflect on how they have changed over the years....